

## Overview

### Useful For

Investigating a possible diagnosis of Niemann-Pick disease type A, B, or C using whole blood specimens

Monitoring of individuals with Niemann-Pick type C disease

This test is **not useful** for the identification of carriers.

### Testing Algorithm

For more information see [Newborn Screening Act Sheet Niemann-Pick A/B: Decreased Acid Sphingomyelinase](#)

### Special Instructions

- [Newborn Screening Act Sheet Niemann-Pick A/B Disease: Decreased Acid Sphingomyelinase](#)

### Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

### NY State Available

Yes

## Specimen

### Specimen Type

Whole blood

### Ordering Guidance

This test's clinical sensitivity and specificity for the identification of Niemann-Pick type C (NPC) is 75% and 89%, respectively. If NPC is strongly suspected, the recommended test is OXNP / Oxysterols, Plasma.

This test is also available as a part of a panel, see HSMWB / Hepatosplenomegaly Panel, Blood. If this test (OXYWB) is ordered with either GPSYW / Glucopsychosine, Blood or CTXWB / Cerebrotendinous Xanthomatosis, Blood, the individual tests will be canceled and HSMWB ordered.

### Specimen Required

#### Container/Tube:

**Preferred:** Lavender top (EDTA)

**Acceptable:** Green top (sodium heparin, lithium heparin) or yellow top (ACD B)

**Specimen Volume:** 1 mL

**Collection Instructions:** Send whole blood specimen in original vial. **Do not aliquot.**

Forms

[If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request](#) (T798) with the specimen.

Specimen Minimum Volume

0.25 mL

Reject Due To

Gross hemolysis	OK
Gross lipemia	OK
Gross icterus	OK

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Whole blood	Refrigerated (preferred)	72 hours	
	Ambient	48 hours	

Clinical & Interpretive

Clinical Information

Niemann-Pick disease types A, B, and C (NPA, NPB, and NPC, respectively) are a group of autosomal recessive lysosomal storage disorders affecting metabolism of specific lipids within cells.

NPA and NPB, also known as acid sphingomyelinase deficiency, result in extensive storage of sphingomyelin and cholesterol in the liver, spleen, lungs, and may also affect the brain. NPA disease is more severe than NPB, and it is characterized by early onset with feeding problems, dystrophy, persistent jaundice, development of hepatosplenomegaly, neurological deterioration, deafness, and blindness leading to death by 3 years of age. NPB disease is limited to visceral symptoms, such as hepatosplenomegaly, with survival into adulthood. Some patients have been described with intermediary clinical phenotypes. Large, lipid-laden foam cells are characteristic of the disease. Approximately 50% of patients with this condition have cherry-red spots in the macula.

The combined prevalence of NPA and NPB is estimated to be 1 in 250,000 individuals. NPA and NPB are inherited in an autosomal recessive manner and are caused by biallelic disease-causing variants in the *SMPD1* gene. Although there is a higher frequency of type A among the Ashkenazi Jewish population, both types are panethnic. Individuals with NPA and NPB typically have elevations of the lyso-sphingomyelin (LSM) and LSM 509 combined with potential elevations in cholestane-3-beta, 5-alpha, 6-beta-triol (COT) and 7-ketocholesterol (7-KC). Molecular genetic testing for NPA and NPB disease is also available (CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies; specify gene list ID: IEMCP-W6S9XD).

NPC is caused by a defect in cellular cholesterol trafficking that results in the progressive accumulation of unesterified cholesterol in late endosomes/lysosomes.(1) NPC is considered a lipid storage disorder with variable age of onset, from the neonatal period to adulthood, and highly variable clinical presentation. Most individuals are diagnosed during

childhood with symptoms that include ataxia, vertical supranuclear gaze palsy, dystonia, progressive speech deterioration, and seizures. Infants may present with or without hepatosplenomegaly and respiratory failure. Those without liver and pulmonary disease may present with hypotonia and developmental delay. Adult-onset NPC is associated with a slower progression and is characterized by psychiatric illness, ataxia, dystonia, and speech difficulties.

The incidence of NPC is approximately 1 in 120,000 to 150,000 live births. NPC is an autosomal recessive condition and is caused by variants in either the *NPC1* or *NPC2* genes. Individuals with NPC exhibit elevated levels of oxysterol COT; LSM 509 and 7-KC may also be elevated. The diagnosis of NPC can be confirmed by demonstration of impaired cholesterol esterification and positive filipin staining in cultured fibroblasts (NIEM / Niemann-Pick Type C Detection, Fibroblasts). For molecular confirmation, genetic testing for NPC disease can be performed (CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies; specify gene list ID: IEMCP-H683JG).

### Reference Values

CHOLESTANE-3-BETA, 5-ALPHA, 6-BETA-TRIOL

Cutoff: < or =0.800 nmol/mL

LYSO-SPHINGOMYELIN

Cutoff: < or =0.100 nmol/mL

### Interpretation

An elevation of cholestane-3-beta, 5-alpha, 6-beta-triol is highly suggestive of Niemann-Pick disease type C (NPC) disease.

An elevation of lyso-sphingomyelin (LSM) is highly suggestive of Niemann-Pick disease type A or B (NPA or NPB) disease.

An elevation LSM 509 is suggestive of NPA, NPB, or NPC disease.

### Cautions

Nonspecific neonatal cholestasis may result in elevations of cholestane-3-beta, 5-alpha, 6-beta-triol and lyso-sphingomyelin 509.

### Clinical Reference

1. Wasserstein MP, Schuchman EH. Acid sphingomyelinase deficiency. In: Adam MP, Everman DB, Mirzaa GM, et al., eds. GeneReviews [Internet]. University of Washington, Seattle; 2006. Updated February 25, 2021. Accessed December 12, 2022. Available at [www.ncbi.nlm.nih.gov/books/NBK1370/](http://www.ncbi.nlm.nih.gov/books/NBK1370/)
2. Patterson M: Niemann-Pick disease type C. In: Adam MP, Everman DB, Mirzaa GM, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 2000. Updated December 10, 2020. Accessed December 12, 2022. Available at [www.ncbi.nlm.nih.gov/books/NBK1296/](http://www.ncbi.nlm.nih.gov/books/NBK1296/)
3. Schuchman EH: The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. *Int J Clin Pharmacol Ther*. 2009;47Suppl 1:S48-S57. doi: 10.5414/cpp47048
4. Hollack CEM, de Sonnaville ESV, Cassiman D, et al: Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients. *Mol Genet Metab*. 2012 Nov;107(3):526-533
5. Wasserstein M, Dionisi-Vici C, Giugliani Ret al: Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD). *Mol Genet Metab*. 2019 Feb;126(2):98-105
6. Geberhiwot T, Moro A, Dardis A, et al; International Niemann-Pick Disease Registry (INPDR): Consensus clinical

management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018 Apr 6;13(1):50

Performance

Method Description

Whole blood is spotted onto filter paper and dried overnight. A 3-mm dried blood spot is extracted with internal standard. The extract is subjected to liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis. The MS/MS is operated in the multiple reaction monitoring positive mode to follow the precursor to product species transitions for each analyte and internal standard. The ratio of the extracted peak areas to internal standard determined by the LC-MS/MS is used to calculate the concentration of in the sample.(Unpublished Mayo method)

PDF Report

No

Day(s) Performed

Tuesday; Specimens must be received by Monday for preanalytical processing

Report Available

3 to 9 days

Specimen Retention Time

Whole blood: 7 days; Dried Blood Spot: Normal results: 2 months Abnormal result: Indefinitely

Performing Laboratory Location

Rochester

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

82542

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
---------	-----------------	--------------------

OXYWB	Oxysterols, B	92738-4
-------	---------------	---------

Result ID	Test Result Name	Result LOINC® Value
BA4354	Interpretation (OXYWB)	59462-2
BA4352	Cholestane-3beta,5alpha,6beta-triol	92756-6
BA4353	Lyso-sphingomyelin	92748-3
BA4355	Reviewed By	18771-6